Key Milestones

Beijing Inno Medicine Co. Ltd. was incorporated.
An in-house R&D team was established and awarded
funds by NSFC and Beijing Science and Technology Commission.

A pilot plant was set up.
Technology transfer from Anzhen Hospital was completed.
Round Pre-A fundraising done with Beijing Science and Technology Investment Group.

Inno Med was moved to Haidian R&D Center.

Formulation YN001 was finalized and scaled up at the pilot plant.
RMB 200 million was raised in Round A.

YN001 secured IND approval from US FDA
Phase I clinical trial was started in Australia
Construction of Shanghai manufacturing site commenced

Phase Ia of YN001 clinical study finished
The Shanghai site was completed and put into operation
YN001 obtained clinical trial approval from NMPA